| Literature DB >> 26692154 |
Minoo Yaghmaei1, Saeedeh Salimi2, Lida Namazi3, Farzaneh Farajian-Mashhadi2.
Abstract
The aim of present study was to investigate the role of the X-ray repair cross-complementing protein1 (XRCC1) and Tumor protein p53 (Tp53) polymorphisms in Uterine Leiomyoma (UL) susceptibility in southeastern Iran. This case control study was performed on 139 women with UL and 149 age, BMI and ethnicity matched healthy women. All women were genotyped for the XRCC1 Arg399Gln, XRCC1 Arg194Trp and Tp53 Arg72Pro polymorphisms. The frequency of Tp53 72 Pro/Pro genotype was significantly higher in UL women compared to controls. The risk of UL was 1.5 fold higher in women with the Pro/Pro genotype (OR, 1.5 [95% CI, 1.1 to 2.1], p = 0.012). Moreover, the frequency of the Pro allele was significantly higher in the UL women. Although the frequency of XRCC1 Arg399Gln genotypes did not significantly differ between UL and control groups before adjusting for age, there was an association between the XRCC1 Arg/Gln genotype and UL after adjusting for age (OR, 1.8 [95% CI, 1.1 to 3]). No association was observed between the XRCC1 Arg194Trp polymorphism and UL. The Pro/Pro genotype of Tp53 Arg72Pro polymorphism was associated with UL susceptibility. In addition, the XRCC1 Arg/Gln genotype was associated with increased risk of UL after adjusting for age.Entities:
Year: 2015 PMID: 26692154 PMCID: PMC4763320 DOI: 10.1590/S1415-475738420140359
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Clinical and demographic characteristics of the uterine leiomyoma women and control group.
| UL women (n = 139) | Controls (n = 149) | p-value | |
|---|---|---|---|
| Age (years) | 38.4 ± 9.7 | 37.3 ± 6.7 | NS |
| Marriage status, n (%) | 134 (96.4) | 145 (97.3) | NS |
| BMI (kg/m2) | 25.0 ± 5.8 | 25.5 ± 5 | NS |
| Parity(n) | 3.4 ± 2.6 | 3.9 ± 2.3 | NS |
| Age of menarche (years) | 13.6 ± 1.1 | 13.3 ± 1.5 | NS |
| Duration of menses (days) | 6.1 ± 1.6 | 5.6 ± 1.5 | NS |
| Menstrual cycle (days) | 28.6 ± 2.2 | 28.0 ± 2.6 | NS |
| Bleeding, n (%) | 82 (59) | 5 (3.4) | 0.0001 |
| Pain, n (%) | 41 (30) | 11 (7.4) | 0.0001 |
Genotypic and allelic frequencies of Tp53 Arg/Pro and XRCC1 Arg399Gln polymorphisms in uterine leiomyoma women and control group.
| UL women (n = 139) | controls (n = 149) | p value | OR (95% CI) | p value | OR (95% CI) | |
|---|---|---|---|---|---|---|
|
| ||||||
| Arg/Arg, n (%) | 36 (26) | 53(36) | 1 | 1 | ||
| Arg/Pro, n (%) | 65 (47) | 72(48) | 0.3 | 1.3(0.8–2.3) | 0.3 | 1.3(0.8–2.3) |
| Pro/Pro, n (%) | 38(27) | 24(16) | 0.012 | 1.5(1.1–2.1) | 0.014 | 1.5(1.1–2.1) |
|
| ||||||
| Arg, n (%) | 137(49.3) | 178(59.7) | 1 | |||
| Pro, n (%) | 141(50.7) | 120(40.3) | 0.012 | 1.5(1.1–2.1) | ||
|
| ||||||
| Arg/Arg, n (%) | 63(45.3) | 85(57) | 1 | 1 | ||
| Arg/Gln, n(%) | 60(43.2) | 50(34) | 0.06 | 1.6(1–2.7) | 0.03 | 1.8(1.1–3) |
| Gln/Gln, n (%) | 16(11.5) | 14(9) | 0.3 | 1.2(0.8–1.8) | 0.2 | 1.3(0.9–1.9) |
|
| ||||||
| Arg, n (%) | 186(67) | 220(74) | 1 | |||
| Gln, n (%) | 92(33) | 78(26) | 0.07 | 1.4(1–2) | ||
|
| ||||||
| Arg/Arg, n (%) | 85(61) | 94(63) | 1 | 1 | ||
| Arg/Trp, n (%) | 51(37) | 51(34) | 0.7 | 1.1(0.7–1.8) | 0.7 | 1.1(0.7–1.8) |
| Trp/Trp, n (%) | 3(2) | 4(3) | 0.8 | 0.9(0.4–2) | 0.8 | 0.9(0.4–1.9) |
|
| ||||||
| Arg, n (%) | 221(79.5) | 239(80) | 1 | |||
| Trp, n (%) | 57(20.5) | 59(20) | 0.84 | 1.1(0.7–1.6) |
Adjusted for age.
Haplotypes frequency of XRCC1 Arg399Gln and Arg194Trp polymorphisms in uterine leiomyoma women and control group.
| XRCC1 Arg399Gln | XRCC1 Arg194Trp | UL women (n = 139) | controls (n = 149) | p value | OR (95% CI) |
|---|---|---|---|---|---|
| Arg | Arg | 64% | 67.6% | 1 | |
| Arg | Trp | 5.8% | 6.8% | 0.8 | 0.9(0.3–2.4) |
| Gln | Arg | 15.8% | 12.2% | 0.4 | 1.2(0.8–1.7) |
| Gln | Trp | 14.4% | 13.5% | 0.7 | 1(0.8–1.3) |